FDA Approves Drug for Pancreatic Cancer Treatment
Dec. 30, 2019 — There’s a brand new remedy possibility for some sufferers with pancreatic most cancers — those that lift a selected genetic mutation can now be handled with the drug olaparib (Lynparza).
The FDA licensed olaparib for use as a first-line remedy of most cancers that has grown past the pancreas in sufferers with what’s referred to as a germline BRCA mutation.
Olaparib is already licensed for use in BRCA-mutated ovarian and breast cancers.
But there are a number of different therapies for those two most cancers varieties, while there are few choices for pancreatic most cancers. It’s some of the devastating cancers — survival charges are the bottom of the most typical most cancers varieties. (The Five-year survival fee is handiest 2% to nine%.)
“Metastatic pancreatic most cancers sufferers had been ready a very long time for new remedy choices for their devastating illness,” stated Julie Fleshman, president and CEO of Pancreatic Cancer Action Network, a affected person reinforce staff.
“Today’s approval of olaparib provides an exciting new treatment option for patients with germline BRCA-mutated metastatic pancreatic cancer,” she stated in a observation.
About four% to nine% of people that have metastatic pancreatic most cancers are concept to hold the BRCA mutation.